What the FDA labels say about taking them together
Fluoxetine and insulin degludec
Insulin degludec's FDA label of July 1, 2022 names fluoxetine in its drug interactions section; fluoxetine's label does not name insulin degludec itself but warns about its class (insulin analogs). The insulin degludec label: “Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline …”
Check it at the source: the fluoxetine FDA label on DailyMed (effective January 8, 2026, Dista Products Company); the insulin degludec FDA label on DailyMed (effective July 1, 2022, Novo Nordisk Pharma, Inc.).
What does the fluoxetine label say about insulin degludec?
Fluoxetine's label does not name insulin degludec itself; it warns about its class (insulin analogs):
Fluoxetine label, warnings and precautionsAs is true with many other types of medication when taken concurrently by patients with diabetes, insulin and/or oral hypoglycemic, dosage may need to be adjusted when therapy with PROZAC is instituted or discontinued.
Source: FDA drug label (Prozac), NDA018936 (Eli Lilly And Co), as published by Dista Products Company, effective January 8, 2026 (SPL set c88f33ed-6dfb-4c5e-bc01-d8e36dd97299), via openFDA; the full label on DailyMed
What does the insulin degludec label say about fluoxetine?
Insulin degludec label, drug interactionsDrugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. Intervention: Dosage reductions and increased frequency of glucose monitoring may be required when Insulin Degludec is co-administered with these drugs.
Source: FDA drug label (Insulin Degludec), Novo Nordisk Pharma, Inc., effective July 1, 2022 (SPL set c1be283d-4b1d-4996-b2a7-4488dbff3037), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fluoxetine | Insulin degludec | |
|---|---|---|
| Labeled for | Depression, Anxiety, Bipolar disorder | Type 2 diabetes, Type 1 diabetes |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0519 per capsule 40 mg capsule | $11.39 per mL 100 unit/mL pen |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once